ClinicalTrials.gg
CompletedNCT00225147Updated Feb 22, 2013Results posted

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

A Phase 2/3 interventional study of Recombinant Human C1 Inhibitor and placebo in Hereditary Angioedema and Angioneurotic Edema, sponsored by Pharming Technologies B.V.. Completed at 1 site in Netherlands. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2013-02-22.

Sponsored by Pharming Technologies B.V. (part of Pharming Group N.V.) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary — none open to participants now, none under way, none of them phase 3. Complement C1 Inhibitor Protein · Angioedemas, Hereditary.

Enrollment
5th of 17
77 · median 32
Started
2005
with 4 others
Phase 2/3
2 of 17
none open now
Registered
2nd of 17
by date
Lead sponsor
4 of 17
Pharming Technologies B.V.

Among the 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary, this one is the 5th largest by enrollment, is one of 5 that started in 2005, is one of 2 in phase 2/3, and was the 2nd registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

None of the 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary is open now. The open studies under Angioedemas, Hereditary, anywhere →

About Complement C1 Inhibitor Protein

Complement C1 Inhibitor Protein: first FDA approval 2014 (Ruconest), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary as a file.
02

Study summary

Hereditary angioedema ("HAE") is a genetic disorder characterized by sudden recurrent attacks of local swelling (angioedema). These attacks are often painful and disabling, and, in some cases, life-threatening. "HAE" is caused by mutations in the "C1INH" gene that lead to a decrease in the blood level of functional "C1INH". This multi-center study was designed to assess the safety and tolerability, efficacy, and pharmacokinetics/pharmacodynamics of recombinant human C1 inhibitor ("rhC1INH") in the treatment of acute hereditary angioedema attacks.

Funding Source - FDA OOPD

Read the detailed description

A prospectively planned interim analysis will be performed on the double-blind data.

03

Conditions studied

  • Hereditary Angioedema
  • Angioneurotic Edema
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Clear clinical and laboratory diagnosis of HAE
  • Plasma level of functional C1INH of less than 50% of normal
  • Acute abdominal, urogenital, peripheral, and/or oro-facial/pharyngeal/laryngeal HAE attack

Main Exclusion Criteria:

  • Acquired angioedema
  • Pregnancy or breastfeeding
  • Treatment with any drug within prior 30 days
  • Body weight >120 kg
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    100 IU/kg rhC1INH

    100 IU/kg Recombinant human C1 inhibitor

    Drug: Recombinant Human C1 Inhibitor

  • Experimental
    50 IU/kg rhC1INH

    50 IU/kg Recombinant human C1 inhibitor

    Drug: Recombinant Human C1 Inhibitor

  • Placebo comparator
    Saline

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Time to Beginning of Relief of Symptoms

    The time to beginning of relief of symptoms at the location that showed the first visual analogue scale ("VAS") score decrease of at least 20 mm from baseline score with persistence to the next timepoint, assessment timepoints were taken on pre-scheduled time-points after study drug administration: baseline (0 minutes), 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours and 48 hours. Time to beginning of relief has been calculated as median time, by using the exact timepoints on which each assessment was performed.

    Time frame: up to 48 hours after study drug administration

Secondary outcomes

  1. Time to Minimal Symptoms

    The time to minimal symptoms was the time to minimal symptoms for an attack, assessed using the Visual Analogue Scale ("VAS") score. Symptoms were said to be minimal when the "VAS" score at all locations was below 20 mm. Assessment timepoints were: baseline, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours and 48 hours. Time to minimal symtoms has been calculated by using the exact timepoints on which each assessment was performed.

    Time frame: up to 48 hours after study drug administration

07

Results

Posted Aug 31, 2012

Participant flow

During the double-blind phase of the study, patients were randomized once to receive 100 IU/kg "rhC1INH", 50 IU/kg "rhC1INH" or Saline in a ratio of 1:1:1. After treatment in the double-blind phase, patients with subsequent eligible attacks could be treated with open-label 50 IU/kg "rhC1INH".

Double-blind Phase
Participant flow — Double-blind Phase
Milestone100 IU/kg "rhC1INH"50 IU/kg "rhC1INH"Placebo50 IU/kg Open-label "rhC1INH"
Started1312130
Completed1312130
Not completed0000
Open-label Phase
Participant flow — Open-label Phase
Milestone100 IU/kg "rhC1INH"50 IU/kg "rhC1INH"Placebo50 IU/kg Open-label "rhC1INH"
Started00062
Completed00052
Not completed00010
Withdrew: Lost to follow-up0004
Withdrew: Withdrawal by subject0006

Outcome measures

PrimaryTime to Beginning of Relief of Symptoms

The time to beginning of relief of symptoms at the location that showed the first visual analogue scale ("VAS") score decrease of at least 20 mm from baseline score with persistence to the next timepoint, assessment timepoints were taken on pre-scheduled time-points after study drug administration: baseline (0 minutes), 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours and 48 hours. Time to beginning of relief has been calculated as median time, by using the exact timepoints on which each assessment was performed.

Time frame:
up to 48 hours after study drug administration
Reported as:
Median · minutes
Time to Beginning of Relief of Symptoms
minutes100 IU/kg "rhC1INH"50 IU/kg "rhC1INH"Placebo50 IU/kg Open-label "rhC1INH"
Time to Beginning of Relief of Symptoms68 (55 to 285)122 (29 to 250)258 (30 to 721)62.5 (15 to 1499)
Statistical analysis
  • 100 IU/kg "rhC1INH" vs Placebo · Log Rank · p = 0.001
  • 50 IU/kg "rhC1INH" vs Placebo · Log Rank · p = <0.001
SecondaryTime to Minimal Symptoms

The time to minimal symptoms was the time to minimal symptoms for an attack, assessed using the Visual Analogue Scale ("VAS") score. Symptoms were said to be minimal when the "VAS" score at all locations was below 20 mm. Assessment timepoints were: baseline, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours and 48 hours. Time to minimal symtoms has been calculated by using the exact timepoints on which each assessment was performed.

Time frame:
up to 48 hours after study drug administration
Reported as:
Median · minutes
Time to Minimal Symptoms
minutes100 IU/kg "rhC1INH"50 IU/kg "rhC1INH"Placebo50 IU/kg Open-label "rhC1INH"
Time to Minimal Symptoms245 (125 to 270)246.5 (243 to 484)1101 (970 to 1494)145 (124 to 256)
Statistical analysis
  • 100 IU/kg "rhC1INH" vs Placebo · Log Rank · p = 0.040
  • 50 IU/kg "rhC1INH" vs Placebo · Log Rank · p = <0.001

Adverse events

Collected over Treatment-Emergent-Adverse-Events (TEAEs) were defined as events with start from onset of study drug administration. Serious Adverse events and Adverse events for each arm with onset dates within 7 days of study drug administration have been listed.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
100 IU/kg rhC1INH—0/13 (0%)2/13 (15.4%)
50 IU/kg rhC1INH—0/12 (0%)2/12 (16.7%)
Placebo—0/13 (0%)3/13 (23.1%)
50 IU/kg Open-label "rhC1INH"—4/62 (6.5%)18/62 (29%)
Most frequent serious events
Most frequent serious events
Event100 IU/kg rhC1INH50 IU/kg rhC1INHPlacebo50 IU/kg Open-label "rhC1INH"
pneumonia - severeInfections and infestations0/130/120/131/62
escherichia sepsisInfections and infestations0/130/120/131/62
vertigo - severeNervous system disorders0/130/120/131/62
hypersensitivityImmune system disorders0/130/120/131/62
Most frequent other events
Showing 10 of 13
Most frequent other events
Event100 IU/kg rhC1INH50 IU/kg rhC1INHPlacebo50 IU/kg Open-label "rhC1INH"
headacheNervous system disorders2/130/120/1312/62
back painMusculoskeletal and connective tissue disorders0/131/120/130/62
erythemaSkin and subcutaneous tissue disorders0/131/120/130/62
injection site swellingGeneral disorders0/130/121/130/62
myalgiaMusculoskeletal and connective tissue disorders0/130/121/130/62
rash erythematousSkin and subcutaneous tissue disorders0/130/121/130/62
throat irritationRespiratory, thoracic and mediastinal disorders0/130/121/130/62
vertigoNervous system disorders1/130/120/132/62
diarrheaGastrointestinal disorders0/130/120/133/62
nauseaGastrointestinal disorders0/130/120/132/62

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)100 IU/kg "rhC1INH"50 IU/kg "rhC1INH"Placebo50 IU/kg Open-label "rhC1INH"Total
<=18 years101911
Between 18 and 65 years1112123065
>=65 years10001
Sex: Female, Male
Sex: Female, Male(Participants)100 IU/kg "rhC1INH"50 IU/kg "rhC1INH"Placebo50 IU/kg Open-label "rhC1INH"Total
Female88122250
Male5411727
08

Study locations

1 site
  • For information on sites please contact Pharming Medical Affairs Department
    Leiden, 2300 AL, Netherlands
09

References and documents

Publications

  • Zuraw B, Cicardi M, Levy RJ, Nuijens JH, Relan A, Visscher S, Haase G, Kaufman L, Hack CE. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol. 2010 Oct;126(4):821-827.e14. doi: 10.1016/j.jaci.2010.07.021. PubMed 20920772 ↗
  • Bernstein JA, Relan A, Harper JR, Riedl M. Sustained response of recombinant human C1 esterase inhibitor for acute treatment of hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2017 Apr;118(4):452-455. doi: 10.1016/j.anai.2017.01.029. Epub 2017 Mar 9. PubMed 28284978 ↗
  • Riedl MA, Levy RJ, Suez D, Lockey RF, Baker JW, Relan A, Zuraw BL. Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. Ann Allergy Asthma Immunol. 2013 Apr;110(4):295-9. doi: 10.1016/j.anai.2013.02.007. Epub 2013 Mar 6. PubMed 23535096 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2005, a primary completion of Oct 2009 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2005
First posted
Sep 23, 2005
Start
Jul 2005
Primary completionActual
Oct 2009
CompletionActual
Jan 2010
Results first posted
Aug 31, 2012
Last update
Feb 22, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00225147
Responsible party
Sponsor
First posted
Sep 23, 2005
Start date
Jul 2005
Primary completion
Oct 2009
Completion
Jan 2010
Results posted
Aug 31, 2012
Last update
Feb 22, 2013

Study contacts

Anurag Relan, MD
study director · Pharming Group N.V.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Complement C1 Inhibitor Protein · Conestat alfa · C1 esterase inhibitor (human)

Start the discussion